Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275337 · ClinicalTrials.gov registry record · NA
Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy
A NA study, sponsored by Laureate Institute for Brain Research.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT03275337 is a NA study that has completed, run by Laureate Institute for Brain Research. The registered enrollment target is 60 participants.
The verdict
NCT03275337, a NA study, has completed, sponsored by Laureate Institute for Brain Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Emerging neuroimaging studies have shown that the cerebellum contributes to different aspects of timing, prediction, learning, and extinction of conditioned responses to aversive stimuli, factors that may be relevant to the success of exposure based behavioral therapy. Our goals are to determine the cerebellar contributions to fear extinction by attempting to modulate key pathways in this process by theta burst stimulation. The long term goal is to lay the foundation for future studies in which neuromodulation is used to augment exposure therapy.
Interventions
- DEVICE Transcranial Direct Current Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275337
The ClinicalTrials.gov registry entry for NCT03275337 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laureate Institute for Brain Research, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transcranial Direct Current Stimulation is the first listed.
NCT03275337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275337 about?
NCT03275337 is a clinical study titled "Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy". Emerging neuroimaging studies have shown that the cerebellum contributes to different aspects of timing, prediction, learning, and extinction of conditioned responses to aversive stimuli, factors that may be relevant to the success of exposure based behavioral therapy. Our goals are to determine the...
What is the current status of trial NCT03275337?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2017-08-01. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03275337?
The interventions under investigation include: Transcranial Direct Current Stimulation (DEVICE).
Who is sponsoring clinical trial NCT03275337?
This trial is sponsored by Laureate Institute for Brain Research, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.